随着社会的发展,勃起功能障碍(erectile dysfunction,ED)的发病率越来越高。1995年全世界约有1.52亿男性患有ED,而到2025年估计患者数将达到3.22亿[1]。20世纪90年代随着5型磷酸二酯酶(PDE5)抑制剂的研制成功,主要的治疗方式逐渐转变为口服PDE5抑制剂。他达拉非作为新一代PDE5抑制剂,可以显著改善勃起功能,帮助患者成功完成性生活,但仍有部分患者按需口服他达拉非治疗ED效果不理想。在存在部分雄激素缺乏 With the development of society, the incidence of erectile dysfunction (ED) is getting higher and higher. In 1995, about 152 million men worldwide had ED, and by 2025 the estimated number of patients will reach 322 million [1]. The success of the development of type 5 phosphodiesterase (PDE5) inhibitors in the 1990s led to the gradual conversion of the primary treatment to oral PDE5 inhibitors. Tadalafil, as a new generation of PDE5 inhibitors, can significantly improve erectile function and help patients successfully complete their sexual life. However, some patients still have unsatisfactory oral ED efficacy with tadalafil. There is a partial absence of androgen